However, a recent network meta-analysis showed that other pharmacotherapies such as sodium-glucose transporter sodium-glucose cotransporter-2 (SGLT2) inhibitors, angiotensin receptor-neprilysin inhibitors (ARNIs), and mineralocorticoid receptor antagonists (MRAs) significantly reduced HF hospitalization in HFpEF, which could help this particular patient population unlike sGC stimulators [21]. Here, NR3C2 is linked to hydrops fetalis.